National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - Full report

Journal of Clinical Lipidology

Volumn 9, Issue 2, 2015, Pages 129-169

  Jacobson, Terry A ^a   Ito, Matthew K ^b   Maki, Kevin C ^c   Orringer, Carl E ^d   Bays, Harold E ^e   Jones, Peter H ^f   McKenney, James M ^g   Grundy, Scott M ^h   Gill, Edward A ⁱ   Wild, Robert A ^j   Wilson, Don P ^k   Brown, W Virgil ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c DEPAUL UNIVERSITY   (United States)

^d UNIVERSITY OF MIAMI HEALTH SYSTEM   (United States)

^e LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^k Cook Children's Medical Center ^*  (United States)

more..

Author keywords

Atherogenic cholesterol; Atherosclerotic cardiovascular disease; Clinical recommendations; Coronary heart disease; Dyslipidemia; Lipoproteins; Low density lipoprotein cholesterol

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLASSIFICATION; CONCEPTUAL FRAMEWORK; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DISEASE SEVERITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; LOW RISK PATIENT; METABOLIC SYNDROME X; MORBIDITY; NATIONAL LIPID ASSOCIATION; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK ASSESSMENT; RISK REDUCTION; SCREENING; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; DYSLIPIDEMIAS; GOVERNMENT; PATHOLOGY; RISK FACTOR;

APOLIPOPROTEINS B; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DISEASE MANAGEMENT; DYSLIPIDEMIAS; GOVERNMENT AGENCIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 84928823445     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.02.003     Document Type: Article

References (342)

1. T.A. Jacobson NLA Task Force on Statin Safety - 2014 update J Clin Lipidol 8 3 Suppl 2014 S1 S4
2. P.A. James, S. Oparil, and B.L. Carter 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
3. N.J. Stone, J.G. Robinson, and A.H. Lichtenstein 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 25 Pt B 2014 2889 2934
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
5. A.L. Catapano, Z. Reinzer, G. De Backer European Society of Cardiology (ESC); European Atherosclerosis Society (EAS) ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
6. P.S. Jellinger, D.A. Smith, A.E. Mehta AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis Endocr Pract 18 Suppl 1 2012 1 78
7. T.J. Anderson, J. Gregoire, and R.A. Hegele 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
8. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia - full report J Clin Lipidol 8 2014 29 60
9. D.C. Goff Jr., D.M. Lloyd-Jones, and G. Bennett 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 25 Pt B 2014 2935 2959
10. National Institute for Health Care and Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE clinical guideline 181. Issued July 2014.
11. American Diabetes Association Standards of medical care in diabetes - 2015. Section 8. Cardiovascular disease and risk management Diabetes Care 38 Suppl 1 2015 S49 S57
12. T.A. Jacobson, M.K. Ito, and K.C. Maki National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary J Clin Lipidol 8 2014 473 488
13. G.H. Guyatt, A.D. Oxman, G.E. Vist GRADE Working Group GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
14. M.N. Walsh, A.A. Bove, R.R. Cross American College of Cardiology Foundation ACCF 2012 health policy statement on patient-centered care in cardiovascular medicine: a report of the American College of Cardiology Foundation Clinical Quality Committee J Am Coll Cardiol 59 2012 2125 2143
15. A.D. Sniderman, K.J. LaChapelle, N.A. Rachon, and C.D. Furberg The necessity for clinical reasoning in the era of evidence-based medicine Mayo Clin Proc 88 2013 1108 1114
16. J.H. Robinson, L.C. Callister, J.A. Berry, and K.A. Dearing Patient-centered care and adherence: definitions and applications to improve outcomes J Am Acad Nurse Pract 20 2008 600 607
17. S.B. Calvert, J.M. Kramer, K.J. Anstrom, L.A. Kaltenbach, J.A. Stafford, and N.M. Allen LaPointe Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial Am Heart J 163 2012 657 665
18. J.D. Cohen, E.A. Brinton, M.K. Ito, and T.A. Jacobson Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users J Clin Lipidol 6 2012 208 215
19. A.S. Go, D. Mozaffarian, V.L. Roger American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics - 2014 update; a report from the American Heart Association Circulation 129 2014 e28 e292
20. S.M. Grundy, J.I. Cleeman, C.N. Merz Coordination Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
21. JBS3 Board Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3) Heart 100 2014 ii1 ii67
22. B.H. Chung, G. Tallis, V. Yalamoori, G.M. Anantharamaiah, and J.P. Segrest Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins Arterioscler Thromb 14 1994 622 635
23. J.H. Rapp, A. Lespine, and R.L. Hamilton Triglyceride-rich lipoproteins isolated by selected affinity anti-apolipoprotein B immunoadsorption from human atherosclerotic plaque Arterioscler Thromb 14 1994 1767 1774
24. R.J. Havel Remnant lipoproteins as therapeutic targets Curr Opin Lipidol 11 2000 615 620
25. M.M. Veniant, M.A. Sullivan, and S.K. Kim Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100 J Clin Invest 106 2000 1501 1510
26. T. Twickler, G.M. Dallinga-Thie, M.J. Chapman, and J.S. Cohn Remnant lipoproteins and atherosclerosis Curr Atheroscler Rep 7 2005 140 147
27. A. Varbo, M. Benn, A. Tybaerg-Hansen, A.B. Jorgensen, R. Frikke-Schmidt, and B.G. Nordestgaard Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 2013 427 436
28. A. Varbo, M. Benn, and B.G. Nordestgaard Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment Pharmacol Ther 141 2014 358 367
29. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
30. J. Jeppesen, H.O. Hein, P. Suadicani, and F. Gyntelberg Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study Circulation 97 1998 1029 1036
31. Y. Cui, R.S. Blumenthal, and J.A. Flaws Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Arch Intern Med 161 2001 1413 1419
32. W.R. Farwell, H.D. Sesso, J.E. Buring, and J.M. Gaziano Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction Am J Cardiol 96 2005 1129 1134
33. P.M. Ridker, N. Rifai, N.R. Cook, G. Bradwin, and J.E. Buring Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women JAMA 294 2005 326 333
34. J. Liu, C.T. Sempos, R.P. Donahue, J. Dorn, M. Trevisan, and S.M. Grundy Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease Am J Cardiol 98 2006 1363 1368
35. I. Holme, A.H. Aastveit, I. Jungner, and G. Walldius Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS) J Intern Med 264 2008 30 38
36. Emerging Risk Factors Collaboration E. Di Angelantonio, N. Sarwar, and P. Perry Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
37. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
38. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115 126
39. I. Tabas, K.J. Williams, and J. Boren Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 2007 1832 1844
40. J. Frostegard Immunity, atherosclerosis and cardiovascular disease BMC Med 11 2013 117
41. D.F. Van Wijk, B. Sjouke, and A. Figueroa Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia J Am Coll Cardiol 64 2014 1418 1426
42. D. Steinberg The LDL modification of atherogenesis: an update J Lipid Res 50 2009 S376 S381
43. J. Wang, A. Razuvaev, and L. Folkersen The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation Atherosclerosis 220 2012 102 109
44. E. Falk, M. Nakano, J.F. Bentzon, A.V. Finn, and R. Virmani Update on acute coronary syndromes: the pathologists' view Eur Heart J 34 2013 719 728
45. P. Libby Molecular bases of the acute coronary syndromes Circulation 91 1995 2844 2850
46. P. Libby, U. Schoenbeck, F. Mach, A.P. Selwyn, and P. Ganz Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization Am J Med 104 2A 1998 14S 18S
47. P. Théroux, and V. Fuster Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction Circulation 97 1998 1195 1206
48. V. Fuster, Z.A. Fayad, and J.J. Badimon Acute coronary syndromes: biology Lancet 353 suppl II 1999 SII5 SII9
49. Pooling Project Research Group Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project J Chronic Dis 31 1978 201 306
50. J. Stamler, D. Wentworth, and J.D. Neaton Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 256 1986 2823 2828
51. K.M. Anderson, W.P. Castelli, and D. Levy Cholesterol and mortality: 30 years of follow-up from the Framingham Study JAMA 257 1987 2176 2180
52. K.M. Anderson, P.W. Wilson, R.J. Garrison, and W.P. Castelli Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample. The Framingham Offspring Study Atherosclerosis 68 1987 59 66
53. M.R. Law, N.J. Wald, and S.G. Thompson By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308 1994 367 372
54. P.N. Hopkins, P.P. Toth, C.M. Ballantyne, D.J. Rader National Lipid Association Expert Panel on Familial Hypercholesterolemia Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia J Clin Lipidol 5 3 Suppl 2011 S9 S17
55. M.C. Izar, V.A. Machado, and F.A. Fonseca Genetic screening for homozygous and heterozygous familial hypercholesterolemia Appl Clin Genet 3 2010 147 157
56. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hoobs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
57. B.A. Ference, F. Majeed, R.D. Brook, L. Hedquist, R. Penumetcha, and J.M. Flack Effect of naturally random allocation to lower LDL-C mediated polymorphisms in NPC1L1, HMGCR or both on the risk of coronary heart disease: a 2x2 factorial Mendelian randomization study Circulation 130 2014 A19754
58. The Myocardial Infarction Genetics Consortium Investigators Inactivating mutations in NPC1L1 and protection from coronary heart disease N Engl J Med 371 2014 2072 2082
59. M.A. Austin Plasma triglyceride and coronary heart disease Arterioscler Thromb 11 1991 2 14
60. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
61. B.G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjærg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308
62. B.G. Nordestgaard, and A. Varbo Triglycerides and cardiovascular disease Lancet 384 2014 626 635
63. J.J. Freiberg, A. Tybjærg-Hansen, J.S. Jensen, and B.G. Nordestgaard Nonfasting triglycerides and risk of ischemic stroke in the general population JAMA 300 2008 2142 2152
64. M.J. Chapman, H.N. Ginsberg, P. Amarenco for the European Atherosclerosis Society Consensus Panel Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 332 2011 1345 1361
65. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration N. Sarwar, M.S. Sanghu, and S.L. Ricketts Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies Lancet 374 2010 1634 1639
66. C.T. Johansen, S. Kathiresan, and R.A. Hegele Genetic determinants of plasma triglycerides J Lipid Res 52 2011 189 206
67. A.B. Jorgensen, R. Frikke-Schmidt, A.S. West, P. Grande, B.G. Nordestgaard, and A. Tybjaerg-Hansen Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction Eur Heart J 34 2013 1826 1833
68. A.B. Jorgensen, R. Frikke-Schmidt, B.C. Nordestgaard, and A. Tybjaerg-Hansen Loss-of-function mutations in APOC3 and risk of ischemic vascular disease N Engl J Med 37 2014 32 41
69. R.A. Hegele, H.N. Ginsberg, M.J. Chapman on behalf of the European Atherosclerosis Society Consensus Panel The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management Lancet Diabetes Endocrinol 2 2014 655 666
70. S. Mora, J.E. Buring, and P.M. Ridker Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events Circulation 129 2014 553 561
71. J.E. Rossouw, B. Lewis, and B.M. Rifkind The value of lowering cholesterol after myocardial infarction N Engl J Med 323 1990 1112 1119
72. D.J. Gordon Cholesterol lowering and total mortality B.M. Rifkind, Lowering cholesterol in high-risk individuals and populations 1995 Marcel Dekker, Inc New York 333 348
73. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
74. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
75. P.S. Sever, B. Dahlof, N.R. Poulter ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the ANGLO-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial Lancet 361 2003 1149 1158
76. P.M. Ridker, E. Danielson, F.A. Fonseca JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
77. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
78. S.J. Lewis, L.A. Moye, and F.M. Sacks Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial Ann Intern Med 129 1998 681 689
79. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
80. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
81. T.R. Pedersen, O. Faergeman, J.J. Kastelein Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445 Erratum in JAMA 2005;294:3092
82. J.C. LaRosa, S.M. Grundy, D.D. Waters Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
83. Cannon CP on behalf of the IMPROVE IT Investigators IMPROVE-IT Trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Late-breaking clinical trial abstracts and clinical science special reports abstracts from the American Heart Association's Scientific Sessions 2014 Circulation 130 2014 2105 2126 Presented at AHA 2014. Chicago, IL
84. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results. I: Reduction in the incidence of coronary heart disease JAMA 251 1984 351 364
85. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering JAMA 251 1984 365 374
86. H. Buchwald, R.L. Varco, and J.R. Boen Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias Arch Intern Med 158 1998 1253 1261
87. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 295 2001 1711 1718
88. P.W. Serruys, P. de Feyter, C. Macaya Lescol Intervention Prevention Study (LIPS) Investigators Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 2002 3215 3222
89. J. Shepherd, G.J. Blauw, M.B. Murphy The PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
90. H. Holdaas, B. Fellstrom, A.G. Jardine Assessment of Lescol in Renal Transplantation (ALERT) Study Investigators Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo controlled trial Lancet 361 2003 2024 2031
91. H.M. Colhoun, D.J. Betteridge, P.N. Durrington CARDS Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
92. C. Baigent, A. Keech, P.M. Kearney Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
93. J.A. de Lemos, M.A. Blazing, S.D. Wiviott for the A to Z Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
94. K.K. Ray, C.P. Cannon, C.H. McCabe PROVE IT-TIMI 22 Investigators Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial J Am Coll Cardiol 46 2005 1405 1410
95. P. Amarenco, J. Bogousslavsky, and A. Callahan 3rd High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
96. D. Mozaffarian, L.J. Appel, and L. Van Horn Components of a cardioprotective diet: new insights Circulation 123 2011 2870 2891
97. S.M. Boekholdt, G.K. Hovingh, and S. Mora Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials J Am Coll Cardiol 64 2014 485 494
98. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
99. D.M. Lloyd-Jones, Y. Hong, D. Labarthe on behalf of the American Heart Association Strategic Planning Task Force and Statistics Committee Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond Circulation 121 2010 586 613
100. L.J. Appel, F.M. Sacks, V.J. Carey OmniHeart Collaborative Research Group Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial JAMA 294 2005 2455 2464
101. M.S. Brown, and J.L. Goldstein Biomedicine. Lowering LDL - not only how low, but how long? Science 311 2006 1721 1731
102. H.C. McGill Jr., C.A. McMahan, G.T. Malcom, M.C. Oalmann, J.P. Strong for the PDAY Research Group Effects of serum lipoproteins and smoking on atherosclerosis in young men and women Arterioscler Thromb Vasc Biol 17 1997 95 106
103. H.C. McGill Jr., and C.A. McMahan Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Determinants of atherosclerosis in the young Am J Cardiol 82 1998 30T 36T
104. H.C. McGill Jr., C.A. McMahan, and A.W. Zieske The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth Arterioscler Thromb Vasc Biol 20 2000 1998 2004
105. M.J. Klag, D.E. Ford, and L.A. Mead Serum cholesterol in young men and subsequent cardiovascular disease N Engl J Med 328 1993 313 318
106. J. Stamler, M.L. Daviglus, D.B. Garside, A.R. Dyer, P. Greenland, and J.D. Neaton Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity JAMA 284 2000 311 318
107. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423
108. A. Keys Seven countries: a multivariate analysis of death and coronary heart disease 1980 Harvard University Press Cambridge, Massachusetts
109. A. Keys, A. Menotti, and C. Aravanis The seven countries study: 2,289 deaths in 15 years Prev Med 13 1984 141 154
110. C.J. Packard, I. Ford, H. Murray, and C. McCowan Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year follow-up of the West of Scotland Coronary Prevention Study. Late-breaking clinical trial abstracts and clinical science special reports abstracts from the American Heart Association's Scientific Sessions 2014 Circulation 130 2014 2105 2126 Presented at AHA 2014. Chicago, IL
111. P.P. Toth, G. Thanassoulis, J. Williams, C.D. Furberg, and A. Sniderman The risk-benefit paradigm vs the causal exposure paradigm: LDL as a primary cause of vascular disease J Clin Lipidol 8 2014 594 605
112. B.G. Brown, and X.Q. Zhao Lipid therapy to stabilize the vulnerable atherosclerotic plaque: new insights into the prevention of cardiovascular events S.M. Grundy, Cholesterol-lowering therapy: evaluation of clinical trial evidence 2000 Marcel Dekker New York
113. D.M. Lloyd-Jones, E.P. Leip, and M.G. Larson Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation 113 2006 791 798
114. M.J. Pencina, R.B. D'Agostino Sr., M.G. Larson, J.M. Massaro, and R.S. Vasan Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study Circulation 119 2009 3078 3084
115. J. Choi, S.S. Daskalopoulou, G. Thanassoulis GENESIS-PRAXY Investigators Sex- and gender-related risk factor burden in patients with premature acute coronary syndrome Can J Cardiol 30 2014 109 117
116. Cholesterol Treatment Trialists' Collaboration B. Mihaylova, J. Emberson, and L. Blackwell The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
117. J.G. Robinson, B. Smith, N. Maheshwari, and H. Schrott Pleiotropic effects of statins: benefit beyond cholesterol reduction? J Am Coll Cardiol 46 2005 1855 1862
118. S. Ma, and C.C. Ma Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily Cytokine Growth Factor Rev 22 2011 167 175
119. K.E. Porter, and N.A. Turner Statins and myocardial remodelling: cell and molecular pathways Expert Rev Mol Med 13 2011 e22
120. J. Davignon Pleiotropic effects of pitavastatin Br J Clin Pharmacol 73 2012 518 535
121. C.G. Mihos, A.M. Pineda, and O. Santana Cardiovascular effects of statins, beyond lipid-lowering properties Pharmacol Res 88 2014 12 19
122. J.R. Guyton, H.E. Bays, S.M. Grundy, and T.A. Jacobson An assessment by the Statin Intolerance Panel: 2014 update J Clin Lipidol 8 3 Suppl 2014 S72 S81
123. S. Ahmed, C.P. Cannon, S.A. Murphy, and E. Braunwald Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial Eur Heart J 27 2006 2323 2329
124. J.A. Beckman, F. Paneni, F. Cosentino, and M.A. Creager Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II Eur Heart J 34 2013 2444 2452
125. S. Bangalore, R. Fayyad, R. Laskey Treating to New Targets Steering Committee and Investigators Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial Eur Heart J 35 2014 1801 1808
126. J.B. Green Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox Postgrad Med 126 2014 190 204
127. S. Yusuf, S. Hawken, S. Ounpuu INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study Lancet 364 2004 937 952
128. I. Skoumas, C. Masoura, and C. Pitsavos Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia Int J Cardiol 12 2007 178 183
129. I. Skoumas, C. Masoura, and K. Aznaouridis Impact of cardiometabolic risk factors on major cardiovascular events in patients with familial combined hyperlipidemia Circ J 77 2013 163 168
130. H. González-Pacheco, J. Vargas-Barrón, and M. Vallejo Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease Ther Clin Risk Manag 10 2014 815 823
131. G.T. Russo, A. Giandalia, and E.L. Romeo Lipid and non-lipid cardiovascular risk factors in postmenopausal type 2 diabetic women with and without coronary heart disease J Endocrinol Invest 37 2014 261 268
132. K.K. Ray, S.R.K. Seshasi, and S. Wijesuriya Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials Lancet 373 2009 1765 1772
133. E. Mannucci, I. Dicembrini, A. Lauria, and P. Pozzilli Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care 36 suppl 2 2013 S259 S263
134. American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 37 Suppl 1 2014 S14 S80
135. M. de Lorgeril, P. Salen, J.L. Martin, I. Monjaud, J. Delaye, and N. Mamelle Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study Circulation 99 1999 779 785
136. M. de Lorgeril Mediterranean diet and cardiovascular disease: historical perspective and latest evidence Curr Atheroscler Rep 15 2013 370
137. R. Estruch, E. Ros, J. Salas-Salvado the PREDIMED Study Investigators Primary prevention of cardiovascular disease with a Mediterranean diet N Engl J Med 368 2013 1279 1290
138. M.J. Stampfer, F.B. Hu, J.E. Manson, E.B. Rimm, and W.C. Willett Primary prevention of coronary heart disease in women through diet and lifestyle N Engl J Med 343 2000 16 22
139. F.B. Hu, and W.C. Willett Diet and coronary heart disease: findings from the Nurses' Health Study and Health Professionals' Follow-up Study J Nutr Health Aging 5 2001 132 138
140. D. Mozaffarian, T. Hao, E.B. Rimm, W.C. Willet, and F.B. Hu Changes in diet and lifestyle and long-term weight gain in women and men N Engl J Med 364 2011 2392 2404
141. N.W. Stine, and D.A. Chokshi Elimination of lipid levels from quality measures. Implications and alternatives JAMA 312 2014 1971 1972
142. M.Y. Wei, M.K. Ito, J.D. Cohen, E.A. Brinton, and T.A. Jacobson Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education J Clin Lipidol 7 2013 472 483
143. M.A. Brookhart, A.R. Patrick, and S. Schneeweiss Physician follow-up and provider continuity are associated with long-term medication adherence. A study of the dynamics of statin use Arch Intern Med 167 2007 847 852
144. R.J. Simpson, and P. Mendys The effect of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review J Clin Lipidol 4 2010 462 471
145. S.S. Martin, M.J. Blaha, and M.B. Elshazly Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile JAMA 310 2013 2061 2068
146. W. Lu, H.E. Resnick, and K.A. Jablonski Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The Strong Heart Study Diabetes Care 26 2003 16 23
147. T. Pischon, C.J. Girman, F.M. Sacks, N. Rifai, M.J. Stampfer, and E.B. Rimm Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men Circulation 112 2005 3375 3383
148. L.S. Rallidis, C. Pitsavos, D.B. Panagiotakos, L. Sinos, C. Stefanadis, and D.T. Kremastinos Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals Atherosclerosis 179 2005 305 309
149. M.J. Blaha, R.S. Blumenthal, E.A. Brinton, and T.A. Jacobson National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non-HDL cholesterol in reporting in lipid management J Clin Lipidol 2 2008 267 273
150. B.J. Arsenault, J.S. Rana, and E.S. Stroes Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women J Am Coll Cardiol 55 2009 35 41
151. N. Mahajan, B.A. Ference, and N. Arora Role of non-high-density lipoprotein cholesterol in predicting cerebrovascular events in patients following myocardial infarction Am J Cardiol 109 2012 1694 1699
152. J.J. Kastelein, W.A. van der Steeg, I. Holme TNT Study Group; IDEAL Study Group Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
153. S.M. Boekholdt, B.J. Arsenault, and S. Mora Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
154. S. Mora, J.D. Otvos, N. Rifai, R.S. Rosenson, J.E. Buring, and P.M. Ridker Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 2009 931 939
155. C.M. Ballantyne, J.S. Raichlen, and V.A. Cain Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial J Am Coll Cardiol 52 2008 56 63
156. S.M. Grundy, G.L. Vega, J.E. Tomassini, and A.M. Tershakovec Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial) Am J Cardiol 104 2009 548 553
157. S.M. Grundy, G.L. Vega, J.E. Tomassini, and A.M. Tershakovec Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial) Am J Cardiol 108 2011 40 46
158. C. Zheng, C. Khoo, K. Ikewaki, and F.M. Sacks Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to formation of LDL subfractions J Lipid Res 48 2007 1190 1203
159. M. Napolitano, K.M. Botham, and E. Bravo Postprandial human triglyceride-rich lipoproteins increase chemoattractant protein secretion in human macrophages Cytokine 63 2013 18 26
160. P.H. Frost, and R.J. Havel Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy Am J Cardiol 81 1998 26B 31B
161. M.H. Davidson, C.M. Ballantyne, and T.A. Jacobson Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an Expert Panel of lipid specialists J Clin Lipidol 5 2011 338 367
162. T.A. Jacobson 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia Int J Clin Pract 65 2011 82 101
163. M. Nauck, G.R. Warnick, and N. Rifai Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation Clin Chem 48 2002 236 254
164. E.T. Bairaktari, K.I. Seferiadis, and M.S. Elisaf Evaluation of methods for the measurement of low-density lipoprotein cholesterol J Cardiovasc Pharmacol Ther 10 2005 45 54
165. M. Agrawal, H.J. Spencer, and F.H. Faas Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study J Investig Med 58 2010 945 949
166. K. Yamada, N. Tsuji, and T. Fujita Comparison of four direct homogeneous methods for the measurement of low-density lipoprotein cholesterol Clin Lab 56 2010 327 333
167. L. Baruch, V.J. Chiong, S. Agarwal, and B. Gupta Discordance of non-HDL and directly measured LDL cholesterol: which lipid measure is preferred when calculated LDL is inaccurate? Cholesterol 2013 2013 502948
168. M. De Vries, B. Klop, and M.C. Cabezas The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice - point of view Atherosclerosis 234 2014 473 475
169. S. Kathiresan A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction N Engl J Med 358 2008 2299 2300
170. T. Pollin, C.M. Damcott, and H. Shen A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection Science 322 2008 1702 1705
171. B.A. Ference, W. Yoo, and I. Alesh Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J Am Coll Cardiol 60 2012 2631 2639
172. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute J. Crosby, G.M. Peloso, and P.L. Auer Loss-of-function mutations in APOC3, triglycerides, and coronary disease N Engl J Med 371 2014 22 31
173. J.G. Robinson, S. Wang, and T.A. Jacobson Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials Am J Cardiol 110 2012 1468 1476
174. V. Ramjee, L.S. Sperling, and T.A. Jacobson Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math J Am Coll Cardiol 58 2011 457 463
175. M.K. Ito, G.M. Delucca, and M.A. Aldridge The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events J Cardiovasc Pharmacol Ther 6 2001 129 135
176. J.C. LaRosa, S.M. Grundy, J.J. Kastelein, J.B. Kostis, and H. Greten Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study) Am J Cardiol 100 2007 747 752
177. C.P. Cannon, E. Braunwald, and C.H. McGabe Pravastatin or Atorvastatin Evaluation and infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504 Erratum in N Engl J Med. 2006;354:778
178. C.P. Cannon The IDEAL cholesterol: lower is better JAMA 294 2005 2492 2494 Erratum in JAMA. 2005;294:2973
179. C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, and E. Braunwald Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445
180. Lipid Research Clinics Program Epidemiology Committee Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study Circulation 60 1979 427 439
181. M.B. Elshazly, S.S. Martin, and M.J. Blaha Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults J Am Coll Cardiol 62 2013 1960 1965
182. A.D. Sniderman, A.C. St-Pierre, B. Cantin, G.R. Dagenais, J.P. Gespres, and B. Lamarche Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk Am J Cardiol 91 2003 1173 1177
183. W.C. Cromwell, J.D. Otvos, and M.J. Keyes LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management J Clin Lipidol 1 2007 583 592
184. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, and D.C. Goff Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
185. S.S. Martin, and E.D. Michos Are we moving towards concordance on the principle that lipid discordance matters? Circulation 129 2014 539 541
186. J.D. Brunzell, M. Davidson, and C.D. Furberg Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
187. C.R. Harper, and T.A. Jacobson Using apolipoprotein B to manage dyslipidemic patients: time for a change? Mayo Clin Proc 85 2010 440 445
188. AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices T.G. Cole, J.H. Contois, and G. Csako Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices Clin Chem 59 2013 752 770
189. C.M. Ballantyne, M. Bertolami, and H.R. Hernandez Garcia Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II Am Heart J 151 2006 975.e1 975.e9
190. C.M. Ballantyne, B. Pitt, J. Loscalzo, V.A. Cain, and J.S. Raichlen Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial) Am J Cardiol 111 2013 506 509
191. M. Farnier, E. Chen, A.O. Johnson-Levonas, C.M. Sisk, and Y.B. Mitchel Effects of extended-release niacin/laropiprant, simvastatin, and the combination of correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia Vasc Health Risk Manag 10 2014 279 290
192. D.R. Witte, M.R. Taskinen, H. Perttunen-Nio, A. Van Tol, S. Livingstone, and H.M. Colhoun Study of agreement between LDL size and measured by nuclear magnetic resonance and gradient gel electrophoresis J Lipid Res 45 2004 1069 1076
193. W. Ensign, N. Hill, and C.B. Heward Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics Clin Chem 52 2006 1722 1727
194. J.J. Sninsky, C.M. Rowland, A.M. Baca, M.P. Caulfield, and H.R. Superko Classification of LDL phenotypes by 4 methods of determining lipoprotein particle size J Investig Med 61 2013 942 949
195. G. Assmann, H. Schulte, H. Funke, and A. von Eckardstein The emergence of triglycerides as a significant independent risk factor in coronary artery disease Eur Heart J 19 Suppl M 1998 M8 M14
196. M.A. Austin, J.E. Hokanson, and K.L. Edwards Hypertriglyceridemia as a cardiovascular risk factor Am J Cardiol 81 1998 7B 12B
197. M. Miller, N.J. Stone, C. Ballantyne American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
198. K. Maki, H. Bays, and M. Dicklin Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence J Clin Lipidol 6 2012 413 426
199. R.M. Gower, H. Wu, and G.A. Foster CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1 Arterioscler Thromb Vasc Biol 31 2011 160 166
200. K.G. Alberti, R.H. Eckel, and S.M. Grundy Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 2009 1640 1645
201. N. Ewald, P.D. Hardt, and H.U. Kloer Severe hypertriglyceridemia and pancreatitis: presentation and management Curr Opin Lipidol 20 2009 497 504
202. M.J. Murphy, X. Sheng, T.M. MacDonald, and L. Wei Hypertriglyceridemia and acute pancreatitis JAMA Intern Med 173 2013 162 164
203. F. Lederle, and H. Bloomfield Drug treatment of asymptomatic hypertriglyceridemia to prevent pancreatitis: where is the evidence? Ann Intern Med 157 2012 662 665
204. D. Preiss, M.J. Tikkanen, and P. Welsh Lipid-modifying therapies and risk of pancreatitis. A meta-analysis JAMA 308 2012 804 811
205. D.J. Gordon, J.L. Probstfield, and R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies Circulation 79 1989 8 15
206. J.C. Fruchart, F. Sacks, and M.P. Hermans The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 2008 1K 34K
207. T. Teramoto, J. Sasaki, and S. Ishibashi Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan - 2012 Version J Atheroscler Thromb 20 2013 517 523
208. P. Natarajan, K.K. Ray, and C.P. Cannon High-density lipoprotein and coronary heart disease: current and future therapies J Am Coll Cardiol 55 2010 1283 1299
209. P. Barter HDL-C: role as a risk modifier Atheroscler Suppl 12 2011 267 270
210. D. Keene, C. Price, M.J. Shun-Shin, and D.P. Francis Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomized controlled trials including 117,411 patients BMJ 349 2014 g4379
211. C. Stefanutti, G. Labbadia, and V.G. Athyros Hypertriglyceridaemia, postprandial lipaemia and non-HDL cholesterol Curr Pharm Des 20 2014 6238 6248
212. B.F. Voight, G.M. Peloso, and M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study Lancet 380 2012 572 580
213. AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267 Correction in N Engl J Med. 2012;367:189
214. G.G. Schwartz, A.G. Olsson, M. Abt dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
215. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 24,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
216. HPS2-THRIVE Collaborative Group M.J. Landray, R. Haynes, and J.C. Hopewell Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
217. N. Kaur, A. Pandey, and H. Negi Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression PLoS One 9 2014 e94585
218. A. Galassi, K. Reynolds, and J. He Metabolic syndrome and risk of cardiovascular disease: a meta-analysis Am J Med 119 2006 812 819
219. A.S. Gami, B.J. Witt, and D.E. Howard Metabolic syndrome and risk of incident cardiovascular events and death J Am Coll Cardiol 49 2007 403 414
220. S. Mottillo, K.B. Filion, and J. Genest The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis J Am Coll Cardiol 56 2010 1113 1132
221. A. Tenenbaum, and E.Z. Fisman "The metabolic syndrome...is dead": these reports are an exaggeration Cardiovasc Diabetol 10 2011 11
222. X. Ma, and S. Zhu Metabolic syndrome in the prevention of cardiovascular diseases and diabetes - still a matter of debate? Eur J Clin Nutr 67 2013 518 521
223. J.A. Shin, J.H. Lee, and S.Y. Lim Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness J Diabetes Investig 4 2013 334 343
224. J. Kaur A comprehensive review on metabolic syndrome Cardiol Res Pract 2014 2014 943162
225. H.S. Dod, R. Bhardwaj, and V. Sajja Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis Am J Cardiol 105 2010 362 367
226. H.E. Bays, P.P. Toth, and P.M. Kris-Etherton Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association J Clin Lipidol 7 2013 304 383
227. L.M. Voeghtly, D.M. Neatrour, and D.J. Decewicz Cardiometabolic risk reduction in an intensive cardiovascular health program Nutr Metab Cardiovasc Dis 23 2013 662 669
228. Y. Wang, Q. Yu, Y. Chen, and F. Cao Pathophysiology and therapeutics of cardiovascular disease in metabolic syndrome Curr Pharm Des 19 2013 4799 4805
229. S. Zhu, Z. Wang, S. Heshka, M. Heo, M.S. Faith, and S.B. Heymsfield Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds Am J Clin Nutr 76 2002 743 749
230. I. Janssen, P.T. Katzmarzyk, and R. Ross Waist circumference and not body mass index explains obesity-related health risk Am J Clin Nutr 79 2004 379 384
231. M.S. Roopakala, A. Suresh, and Ashtalakshmi Anthropometric measurements as predictors of intraabdominal fat thickness Indian J Physiol Pharmacol 53 2009 259 264
232. D. Einhorn, G.M. Reaven, R.H. Cobin American College of Endocrinology Task Force on the Insulin Resistance Syndrome American College of Endocrinology position statement on the insulin resistance syndrome Endocr Pract 9 2003 236 252
233. K.L. Cheal, F. Abbasi, C. Lamendola, R. McLaughlin, G.M. Reaven, and E.S. Ford Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome Diabetes 53 2004 1195 1200
234. M.C. Ryan, M.F. Farin, F. Abbasi, and G.M. Reaven Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease Am J Cardiol 102 2008 40 46
235. E.S. Ford, C. Li, G. Zhao, and J. Tsai Trends in obesity and abdominal obesity among adults in the United States from 1999-2008 Int J Obes 35 2011 736 743
236. S.R. Bozeman, D.C. Hoaglin, T.M. Burton, C.L. Pashos, R.H. Ben-Joseph, and C.S. Hollenbeak Predicting waist circumference from body mass index BMC Med Res Methodol 12 2012 115
237. N.J. Stone Secondary causes of hyperlipidemia Med Clin North Am 78 1984 117 141
238. A.K. Mantel-Teeuwisse, J.M.E. Kloosterman, A.H. Maitland-van der Zee, O.H. Klungel, A.J. Porsius, and A. de Boer Drug-induced lipid changes. A review of the unintended effects of some commonly used drugs on serum lipid levels Drug Saf 24 2001 443 456
239. J.M. Meyer Novel antipsychotics and severe hyperlipidemia J Clin Psychopharmacol 21 2001 369 374
240. C.U. Correll, A.M. Fredrickson, J.M. Kane, and P. Manu Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs J Clin Psychiatry 67 2006 575 583
241. B.S. Wiggins, J.J. Saseen, and S.A. Spinler Pharmacist's guide to lipid management 2008 American College of Clinical Pharmacy Lenexa, KS
242. K. Tziomalos, V.G. Athuros, A. Karagiannis, and D.P. Mikhailidis Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases Open Cardiovasc Med J 5 2011 85 89
243. D. Vodnala, M. Rubenfire, and R.D. Brook Secondary causes of dyslipidemia Am J Cardiol 110 2012 823 825
244. M.K. Ito Chapter 12. Dyslipidemias M. Chisolm-Burns, T. Schwinghammer, B. Wells, P. Malone, J. DiPiro, Pharmacotherapy principles & practice 3rd ed 2013 McGraw-Hill Education Blacklick, OH
245. W.K. Al-Delaimy, J.E. Manson, and C.G. Solomon Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus Arch Intern Med 162 2002 272 279
246. W.K. Al-Delaimy, M.J. Stampfer, J.E. Manson, and W.C. Willett Toenail nicotine levels as predictors of coronary heart disease among women Am J Epidemiol 167 2008 1342 1348
247. T.A. Pearson, G.A. Mensah, and R.W. Alexander Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
248. P.M. Ridker Clinical application of C-reactive protein for cardiovascular disease detection and prevention Circulation 107 2003 363 369
249. P.M. Ridker, S.S. Bassuk, and P.P. Toth C-reactive protein and risk of cardiovascular disease: evidence and clinical application Curr Atheroscler Rep 5 2003 341 349
250. P. Greenland, L. LaBree, S.P. Azen, T.M. Doherty, and R.C. Detrano Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals JAMA 291 2004 210 215
251. P. Greenland, R.O. Bonow, B.H. Brundage American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computer Tomography); Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computer Tomograph ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computer tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computer Tomography) Circulation 115 2007 402 426
252. B.G. Nordestgaard, M.J. Chapman, K. Ray European Atherosclerosis Society Consensus Panel Lipoprotein (a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
253. M.K. Ito, M.P. McGowan, P.M. Moriarty National Lipid Association Expert Panel on Familial Hypercholesterolemia Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia J Clin Lipidol 5 3 Suppl 2011 S38 S45
254. L.A. Cox Jr. Low-dose nonlinear effects of smoking on coronary heart disease risk Dose Response 10 2012 219 232
255. KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease Kidney Int Suppl 3 2013 136 150
256. A.D. Sniderman, S. Tsimikas, and S. Fazio The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies J Am Coll Cardiol 63 2014 1935 1947
257. S.D. de Ferranti, I.H. de Boer, and V. Fonseca Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association Circulation 130 2014 1110 1130
258. S.J. Livingstone, D. Levin, H.C. Looker Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010 JAMA 313 2015 37 44
259. R.N. Foley, P.S. Parfrey, and M.J. Sarnak Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 suppl 3 1998 S112 S119
260. Chronic Kidney Disease Prognosis Consortium Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 2010 2073 2081
261. C. Wanner, V. Krane, W. Marz German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
262. C. Baigent, M.J. Landray, C. Reith SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
263. M. Barylski, S. Nikfar, D.P. Mikhailidis Lipid and Blood Pressure Meta-Analysis Collaboration Group Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy - a meta-analysis of 11 randomized controlled trials involving 21,295 participants Pharmacol Res 72 2013 35 44
264. W. Hou, J. Lv, and V. Perkovic Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis Eur Heart J 34 2013 1807 1817
265. P.M. Ridker, J.E. Buring, N. Rifai, and N.R. Cook Development and validation of improved algorithms for assessment of global cardiovascular risk in women: the Reynolds Risk Score JAMA 297 2007 611 619
266. H. Nakamura, K. Arakawa, H. Itakura MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial Lancet 368 2006 1155 1163
267. D.T. Lackland, M.S. Elkind, R. D'Agostino Sr. American Heart Association Stroke Council; Council on Epidemiology and Prevention; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke 43 2012 1998 2027
268. N.P. Amin, S.S. Martin, M.J. Blaha, K. Nasir, R.S. Blumenthal, and E.D. Michos Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA Risk Assessment Guidelines J Am Coll Cardiol 63 25 Pt A 2014 2789 2794
269. W.V. Brown, V.A. Bittner, J.M. McKenney, and P.E. Ziajka JCL Roundtable: lipid-lowering drugs in those older than 75 years of age J Clin Lipidol 8 2014 533 541
270. P. Muntner, L.D. Colantonio, and M. Cushman Validation of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations JAMA 311 2014 1406 1415
271. P.M. Ridker, and N.R. Cook Statins: new American guidelines for prevention of cardiovascular disease Lancet 383 2013 1762 1765
272. N.R. Cook, and P.M. Ridker Further insight into the cardiovascular risk calculator. The roles of statins, revascularization, and underascertainment in the Women's Health Study JAMA Intern Med 174 2014 1964 1971
273. M. Kavousi, M.J. Leening, and D. Nanchen Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort JAMA 311 2014 1416 1423
274. J.D. Berry, A. Dyer, and X. Cai Lifetime risks of cardiovascular disease N Engl J Med 366 2012 321 329
275. C.M. Gamboa, M.M. Safford, and E.B. Levitan Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease Am J Med Sci 348 2014 108 114
276. J.G. Robinson Contemporary evidence-based guidelines: practice based on the strongest evidence Mayo Clin Proc 89 2014 1176 1182
277. Y. Arad, L.A. Spadaro, K. Goodman, D. Newstein, and A.D. Guerci Prediction of coronary events with electron beam computer tomography J Am Coll Cardiol 36 2000 1253 1260
278. Y. Arad, K.J. Goodman, M. Roth, D. Newstein, and A.D. Guerci Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study J Am Coll Cardiol 46 2005 158 165
279. M.J. Pletcher, J.A. Tice, M. Pignone, and W.S. Browner Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis Arch Intern Med 164 2004 1285 1292
280. S.P. Whelton, K. Nasir, and M.J. Blaha Coronary artery calcium and primary prevention risk assessment: what is the evidence? An updated meta-analysis on patient and physician behavior Circ Cardiovasc Qual Outcomes 5 2012 601 607
281. J. Yeboah, R.L. McClelland, and T.S. Polonsky Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals JAMA 308 2012 788 795
282. J. Yeboah, J.J. Carr, and J.G. Terry Computed tomography-derived cardiovascular risk markers, incident cardiovascular events, and all-cause mortality in nondiabetics: the Multi-Ethnic Study of Atherosclerosis Eur J Prev Cardiol 21 2014 1233 1241
283. M.J. Budoff, S. Mohlenkamp, R. McClelland Multi-Ethnic Study of Atherosclerosis and the Investigator Group of the Heinz Nixdorf RECALL Study A comparison of outcomes with coronary artery calcium scanning in unselected populations: the Multi-Ethnic Study of Atherosclerosis (MESA) and Heinz Nixdorf RECALL study (HNR) J Cardiovasc Comput Tomogr 7 2013 182 191
284. N. Sunkara, N.D. Wong, and S. Malik Role of coronary artery calcium in cardiovascular risk assessment Expert Rev Cardiovasc Ther 12 2014 87 94
285. M.J. Blaha, M.G. Silverman, and M.J. Budoff Is there a role of coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease?: Clinical risk scores are not sufficient to define primary prevention treatment strategies among asymptomatic patients Circ Cardiovasc Imaging 7 2014 398 408
286. K. Nasir, E.D. Michos, R.S. Blumenthal, and P. Raggi Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines J Am Coll Cardiol 46 2005 1931 1936
287. K. Nasir, L.J. Shaw, and S.T. Liu Ethnic differences in the prognostic value of coronary artery calcification for all-cause mortality J Am Coll Cardiol 50 2007 953 960
288. R. Detrano, A.D. Guerci, and J.J. Carr Coronary calcium as a predictor of coronary events in four racial or ethnic groups N Engl J Med 358 2008 1336 1345
289. R.L. McClelland, H. Chung, R. Detrano, W. Post, and R.A. Kronmal Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA) Circulation 113 2006 30 37
290. E.M. deGoma, R.L. Dunbar, D. Jacoby, and B. French Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equations Atherosclerosis 227 2013 172 177
291. S.G. Lakoski, P. Greenland, and N.D. Wong Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: the Multi-Ethnic Study of Atherosclerosis (MESA) Arch Intern Med 167 2007 2437 2442
292. M.G. Silverman, M.J. Blaha, and H.M. Krumholz Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis Eur Heart J 35 2014 2232 2241
293. S.A. Jebb, A.L. Ahern, and A.D. Olson Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial Lancet 378 2011 1485 1492
294. K. Jolly, A. Lewis, and J. Beach Comparison of range of commercial or primary care led weight reduction programmes with minimal intervention control for weight loss in obesity: Lighten Up randomised controlled trial BMJ 343 2011 d6500
295. J.D. Cohen, K.E. Aspry, and A.S. Brown Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop J Clin Lipidol 7 2013 573 609
296. J.G. Robinson Starting primary prevention earlier with statins Am J Cardiol 114 2014 1437 1442
297. S.M. Grundy Treatment targets in the management of dyslipidemias: which targets in whom? Curr Cardiol Rep 14 2012 692 700
298. S.M. Grundy Statins for all? Am J Cardiol 114 2014 1443 1446
299. P.H. Jones, M.H. Davidson, E.A. Stein STELLAR Study Group Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol 92 2003 152 160
300. J. Pang, D.C. Chan, and G.F. Watts Critical review of non-statin treatments for dyslipoproteinemia Expert Rev Cardiovasc Ther 12 2014 359 371
301. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
302. E. Bruckert, J. Labreuche, and P. Amarenco Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 2010 353 361
303. M. Jun, C. Foote, and J. Lv Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
304. N. Li, Q. Li, X.Q. Tian, H.Y. Qian, and Y.J. Yang Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials Am J Cardiovasc Drugs 14 2014 367 376
305. D.J. Rader, and J.J. Kastelein Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia Circulation 129 2014 1022 1032
306. J.C. LaRosa, T.R. Pedersen, R. Somaratne, and S.M. Wasserman Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events Am J Cardiol 111 2013 1221 1229
307. W.J. Kostis How low an LDL-C should we go with statin therapy? Curr Atheroscler Rep 16 2014 388
308. J.S. Benner, J.C. Tierce, and C.M. Ballantyne Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy Pharmacoeconomics 22 Suppl 3 2004 13 23
309. H.E. Bays, P.H. Jones, W.V. Brown, and T.A. Jacobson National Lipid Association annual summary of clinical lipidology 2015 J Clin Lipidol 8 6 Suppl 2014 S1 S36
310. L. Kjems, C. Filozof, M. Wright, and D. Keefe Association between fasting triglycerides and presence of fasting chylomicrons in patients with severe hypertriglyceridemia J Clin Lipidol 8 2014 312 (Abstract 121)
311. A. Viljoen, and A.S. Wierzbicki Diagnosis and treatment of severe hypertriglyceridemia Expert Rev Cardiovasc Ther 10 2012 505 514
312. R.H. Eckel, J.M. Jakicic, and J.D. Ard 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 25 Pt B 2014 2960 2984
313. M. Yokoyama, H. Origasa, M. Matsuzaki Japan EPA lipid intervention study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098 Erratum in Lancet. 2007;370:220
314. ACCORD Study Group H.N. Ginsberg, M.B. Elam, and L.C. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574 Erratum in N Engl J Med. 2010;362:1748
315. J.R. Guyton, A.E. Slee, and T. Anderson Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) J Am Coll Cardiol 62 2013 1580 1584
316. M. Lee, J.L. Saver, A. Towfighi, J. Chow, and B. Ovbiagele Efficacy of fibrates for cardioavscular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis 217 2011 492 498
317. C.H. Rojas-Fernandez, L.B. Goldstein, A.I. Levey, B.A. Taylor, and V. Bittner An assessment by the Statin Cognitive Safety Task Force: 2014 update J Clin Lipidol 8 3 Suppl 2014 S5 S16
318. R.S. Rosenson, S.K. Baker, T.A. Jacobson, S.L. Kopecky, and B.A. Parker An assessment by the Statin Muscle Safety Task Force: 2014 update J Clin Lipidol 8 3 Suppl 2014 S58 S71
319. M.K. Ito, K.C. Maki, E.A. Brinton, J.D. Cohen, and T.A. Jacobson Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study J Clin Lipidol 8 2014 69 76
320. K.A. Kellick, M. Bottorff, and P.P. Toth A clinician's guide to statin drug-drug interactions J Clin Lipidol 8 3 Suppl 2014 S30 S46
321. K.A. Gudzune, A.K. Monroe, R. Sharma, P.D. Ranasinghe, Y. Chelladurai, and K.A. Robinson Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy. A systematic review Ann Intern Med 160 2014 468 476
322. N. Sattar, D. Preiss, and H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 7422
323. D. Preiss, S.R. Seshasai, and P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy; a meta-analysis JAMA 305 2011 2556 2564
324. K.C. Maki, P.M. Ridker, W.V. Brown, S.M. Grundy, and N. Sattar An assessment by the Statin Diabetes Safety Task Force: 2014 update J Clin Lipidol 8 3 Suppl 2014 S17 S29
325. D.D. Waters, J.E. Ho, and S.M. Boekholdt Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes J Am Coll Cardiol 61 2013 148 152
326. J. Sasaki, M. Yokoyama, M. Matsuzaki JELIS Investigators Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS) J Atheroscler Thromb 19 2012 194 204
327. F.M. Sacks, V.J. Carey, and J.C. Fruchart Combination lipid therapy in type 2 diabetes N Engl J Med 363 2010 692 694
328. T.A. Pearson, M.A. Denke, P.E. McBride, W.P. Battisti, W.E. Brady, and J. Palmisano A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial Mayo Clin Proc 80 2005 587 595
329. N. Katsiki, E. Theocharidou, A. Karagiannis, V.G. Athyros, and D.P. Mikhailidis Ezetimibe therapy for dyslipidemia: an update Curr Pharm Des 19 2013 3107 3114
330. U. Laufs, W.S. Weintraub, and C.J. Packard Beyond statins: what to expect from add-on lipid regulating therapy? Eur Heart J 34 2013 2660 2665
331. D.G. Johns, J. Duffy, T. Fisher, B.K. Hubbard, and M.J. Forrest On- and off-target pharmacology of torcetrapid: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors Drugs 72 2012 491 507
332. S. Lim, I. Sakuma, M.J. Quon, and K.K. Koh Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality Int J Cardiol 167 2013 1696 1702
333. J.G. Robinson, H.M. Colhoun, and H.E. Bays Efficacy and safety of aliocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies Clin Cardiol 37 2014 597 604
334. D.R. Verma, and E.A. Brinton Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies Rev Cardiovasc Med 15 2014 86 101
335. P.P. Toth Emerging LDL therapies: mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia J Clin Lipidol 7 3 Suppl 2013 S6 S10
336. A.C. Goldberg Emerging low-density lipoprotein therapies: microsomal triglyceride transfer protein inhibitors J Clin Lipidol 7 3 Suppl 2013 S16 S20
337. A.C. Goldberg, P.N. Hopkins, and P.P. Toth Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on familial hypercholesterolemia J Clin Lipidol 5 2011 133 140
338. S.A. Murphy, C.P. Cannon, S.D. Wiviott, C.H. McCabe, and E. Braunwald Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compare with moderate lipid-lowering statin therapy after acute coronary syndromes form the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22) Trial J Am Coll Cardiol 54 2009 2358 2362
339. S.J. Nicholls, C.M. Ballantyne, and P.J. Barter Effect of two intensive statin regimens on progression of coronary disease N Engl J Med 365 2011 2078 2087
340. R. Puri, S.E. Nissen, and M. Shao Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from study of coronary atheroma by intravascular ultrasound: effect of rosuvastatin versus atorvastatin Arterioscler Thromb Vasc Biol 34 2014 2465 2472
341. A.P. van de Woestijne, A.M. Wassink, H. Monajemi SMART study group Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or non-HDL-cholesterol Int J Cardiol 167 2013 403 408
342. M.V. Ezhov, M.S. Safarova, O.I. Afanasieva, V.V. Kukharchuk, and S.N. Pokrovsky Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting Atherosclerosis 235 2014 477 482